An Open-Label, Multicenter, Randomised, Controlled Study to Evaluate the Efficacy and Safety of the BARRIER® EasyWarm Active Self-Warming Blanket Used for Continuous Active Warming to Prevent General Anaesthesia Induced Hypothermia During the Perioperative Surgical Period
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Anesthesia Induced Hypothermia
- Sponsor
- Molnlycke Health Care AB
- Enrollment
- 271
- Primary Endpoint
- The Difference in the Arithmetic Mean of Core Body Temperature Measurements During the Perioperative Phase Between the Interventional Treatment Group and the Control Treatment Group
- Status
- Completed
- Last Updated
- 10 years ago
Overview
Brief Summary
The investigation was designed as an Open-Label, Multicenter, Randomised, Controlled Investigation to Evaluate the Efficacy and Safety of the BARRIER® EasyWarm Active Self-Warming Blanket Used for Continuous Active Warming to Prevent General Anaesthesia Induced Hypothermia During the Perioperative Surgical Period. Null hypothesis (H0): There is no difference between the two study populations (interventional treatment group versus control treatment group) regarding the average of core body temperature measurements during the perioperative phase.Alternative hypothesis (H1): The average of core body temperature measurements during the perioperative phase is significantly higher in the interventional group compared to that of the control group.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Gender: Both men and women are included into the study
- •Subjects' age: Subjects must be at least 18 years old to be included into the study
- •Type of anaesthesia: Only subjects receiving general anaesthesia are included into the study
- •Type of surgery: Subjects undergoing only the following three types of surgical procedures (i.e. inclusive of laparoscopic procedures) are included into the study:
- •Gynaecological
- •Orthopaedic
- •Ear, nose and throat (ENT)
- •Length of surgery: Subjects scheduled for a surgery with a minimum length of 30 minutes and maximum length of 120 minutes
- •Temperature: Subjects should have a tympanic temperature measurement equal to or greater than 36.0 degrees Celsius when first measured in the preoperative setting the same day as the surgical procedure and before randomisation
- •Informed Consent Form (ICF): The subject must be able to understand and sign an ICF
Exclusion Criteria
- •American Society of Anesthesiologists (ASA) Physical Status Classification rating: Subjects with a ASA rating of 4 or greater are excluded from the study
- •Comorbidity: Known Diabetes with an HbA1c of more than 6 %
- •Temperature: Subjects with a tympanic temperature measurement below 36.0 degrees Celsius taken in the preoperative setting
- •Medical history: Subject reports relevant medical history (e.g., neuropathy, peripheral vascular disease, or other) that presents risk to/of:
- •The subject's normal temperature regulation or
- •Perception of external temperature or
- •Subcutaneous lipoatrophy
- •Medication: Current use of concomitant medications that present relevant risk to/of:
- •The subject's normal temperature regulation or
- •Perception of external temperature or Clinical Investigation Plan with Integrated Amendments 01 and 02, MD12-001, final, 14-Jan-2013 5(32)
Outcomes
Primary Outcomes
The Difference in the Arithmetic Mean of Core Body Temperature Measurements During the Perioperative Phase Between the Interventional Treatment Group and the Control Treatment Group
Time Frame: temperature measurments during pre,-intra and postoperative period, on average 1-5 hours, depending on the surgical intervention.
The subject's core body temperature at any time point is approximated by the arithmetic mean of three repeated tympanic temperature measurements every 15 minutes during the perioperative period